Outlook Therapeutics secures FDA acceptance for wet AMD drug review
Outlook Therapeutics Inc. announced that the FDA accepted the resubmitted BLA for ONS-5010/LYTENAVA for wet AMD treatment. The filing was classified as a Class 1 review with a PDUFA target action date of July 29, 2026. The company is preparing for commercialization, aiming to offer the first FDA-approved ophthalmic formulation of bevacizumab.
*this image is generated using AI for illustrative purposes only.
Outlook Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration (nAMD), also known as wet AMD. The FDA has classified the resubmission as a Class 1 review and set a PDUFA target action date of July 29, 2026. This regulatory milestone marks a critical step toward bringing the first FDA-approved ophthalmic formulation of bevacizumab to market.
The acceptance of the BLA resubmission allows Outlook Therapeutics to proceed toward potential commercialization. The company has already initiated pre-launch activities to prepare for the pending approval. ONS-5010/LYTENAVA is designed to be the first and only FDA-approved ophthalmic formulation of bevacizumab, supported by standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance.
Key Details of the BLA Resubmission
The following table outlines the critical regulatory milestones and details associated with the BLA for ONS-5010/LYTENAVA:
| Aspect | Details |
|---|---|
| Product | ONS-5010/LYTENAVA |
| Indication | Neovascular age-related macular degeneration (nAMD) |
| Review Classification | Class 1 |
| PDUFA Target Action Date | July 29, 2026 |
Strategic Significance
If approved, ONS-5010/LYTENAVA aims to enhance the standard of care for bevacizumab in treating retina diseases. The formulation seeks to provide a regulated alternative to current compounded options, offering standardized manufacturing and comprehensive safety monitoring. Outlook Therapeutics' focus on pre-launch activities underscores its confidence in the application and readiness to address the market need.
How will the approval of ONS-5010/LYTENAVA impact the current market for compounded bevacizumab treatments?
What are the potential pricing and reimbursement challenges Outlook Therapeutics might face post-approval?
How will the company differentiate ONS-5010/LYTENAVA from existing anti-VEGF therapies like ranibizumab and aflibercept?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
